Rixubis (Hemophilia A and B) – Forecast and Market Analysis to 2022

1
Rixubis (Hemophilia A and B) Forecast and
Market Analysis to 2022by GlobalData

• Explore all reports for Hematology Therapeutics
  market _at_
• http//www.rnrmarketresearch.com/reports/life-scie
  nces/pharmaceuticals/therapeutics/hematology-thera
  peutics

2
Rixubis (Hemophilia A and B) Forecast and
Market Analysis to 2022

• The competitive landscape of hemophilia A and B
  recombinant therapy in the US and 5EU is
  dominated by the use of recombinant FVIII and FIX
  replacement factors, and patients with severe
  forms of the disease receive frequent
  prophylactic infusions beginning from the first
  one or two years of life and often continuing
  through adulthood. However, the burden on
  patients and their families to maintain the
  prophylactic treatment schedule is high, and
  there is a significant unmet need for new
  therapies that can reduce the number of weekly
  prophylactic infusions and alleviate some of this
  treatment burden.
• Baxters Rixubis is a recombinant Factor IX
  replacement therapy for prophylactic, on-demand
  and perioperative treatment of adults with severe
  hemophilia B. Rixubis, which received FDA
  approval in June 2013, is the only recombinant
  FIX replacement therapy indicated for
  prophylactic use in hemophilia B patients.
• Request sample copy of this report _at_
  http//www.rnrmarketresearch.com/contacts/request-
  sample?rname145256

3
Rixubis (Hemophilia A and B) Forecast and
Market Analysis to 2022

• Scope
• Overview of Hemophilia A and B, including
  epidemiology, etiology, symptoms, diagnosis,
  pathology and treatment guidelines as well as an
  overview on the competitive landscape.
• Detailed information on Rixubis including product
  description, safety and efficacy profiles as well
  as a SWOT analysis.
• Sales forecast for Rixubis for the top nine
  countries from 2012 to 2022.
• Sales information covered for the US, France,
  Germany, Italy, Spain, the UK, Japan, Argentina
  and China.
• Complete report available _at_ http//www.rnrmarketre
  search.com/rixubis-hemophilia-a-and-b-forecast-and
  -market-analysis-to-2022-market-report.html

4
Rixubis (Hemophilia A and B) Forecast and
Market Analysis to 2022

• Reasons to buy
• Understand and capitalize by identifying products
  that are most likely to ensure a robust return
• Stay ahead of the competition by understanding
  the changing competitive landscape for Hemophilia
  A and B
• Effectively plan your MA and partnership
  strategies by identifying drugs with the most
  promising sales potential
• Make more informed business decisions from
  insightful and in-depth analysis of Rixubis
  performance
• Obtain sales forecast for Rixubis from 2012-2022
  in top nine countries (the US, France, Germany,
  Italy, Spain, the UK, Japan, Argentina and China)
• Buy a copy of this report by GlobalData _at_
  http//www.rnrmarketresearch.com/contacts/purchase
  ?rname145256

5
Rixubis (Hemophilia A and B) Forecast and
Market Analysis to 2022

• Table of Contents
• 1 Table of Contents 41.1 List of Tables 6
• 2 Introduction 72.1 Catalyst 72.2 Related
  Reports 82.3 Upcoming Related Reports 10
• 3 Disease Overview 113.1 Etiology and
  Pathophysiology 113.1.1 Etiology 113.1.2
  Pathophysiology 123.1.3 Prognosis and Quality of
  Life 143.2 Symptoms 153.2.1 Hemophilia A and B
  153.2.2 Inhibitors 16
• Request sample copy of this report _at_
  http//www.rnrmarketresearch.com/contacts/request-
  sample?rname145256

6
Rixubis (Hemophilia A and B) Forecast and
Market Analysis to 2022

• For more details contact Mr. Priyank Tiwari
  sales_at_rnrmarketresearch.com / 18883915441

RnR Market Research RnRMarketResearch.com, an
online repository of market  research reports,
offers in-depth analysis of over 5000 market
segments. RnR  Market Research library has
syndicated reports by leading market research 
publishers across the globe.